Literature DB >> 15640687

CD3 delta immunodeficiency.

Chaim M Roifman1.   

Abstract

PURPOSE OF REVIEW: The review describes advances in understanding the role of the CD3 delta subunit in human T-cell development as deduced from a recently described human immunodeficiency. The review also compares CD3 delta deficiency with other human CD3 subunit deficiencies and with corresponding animal models. RECENT
FINDINGS: In describing CD3 delta deficiency in humans this review shows that patients with profound T-cell depletion, who present at 2-3 months with severe viral infection, lack CD3 delta as a result of a mutation in the extracellular domain of this gene. The genetic aberration was discovered by comparing patients' and normal thymocytes, using mass gene screening with the microarray technique. In humans the absence of CD3 delta results in a complete arrest in thymocyte development at the stage of double negative to double positive transition and the development of gamma delta T-cell receptor-positive T cells is also impaired.
SUMMARY: Unlike patients with CD3 gamma or CD3 epsilon deficiency who have a milder condition, patients with CD3 delta deficiency present with severe lethal susceptibility to infections during early infancy. As expected, this profound immunodeficiency was cured with an allogenic bone marrow transplantation. In contrast to murine CD3 (-/) delta, which retains a normal gamma delta T-cell receptor-positive T-cell population and only partly affects the developmental transition of double positive to single positive thymocytes, CD3 delta in humans appears to be more critically required for the development of both alpha beta and gamma delta T-cell receptor-positive T-cell lineages. The studies also show for the first time that comparing relevant patients' with normal tissue using microarray technology can aid in the discovery of the genetic basis of inherited disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15640687     DOI: 10.1097/00130832-200412000-00002

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  9 in total

Review 1.  Evolution of immunity: no development without risk.

Authors:  Alexander B Sigalov
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

2.  Cells diversify transmembrane signaling through the controlled chaos of protein disorder.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2011-04-01

Review 3.  New therapeutic strategies targeting transmembrane signal transduction in the immune system.

Authors:  Alexander B Sigalov
Journal:  Cell Adh Migr       Date:  2010-04-24       Impact factor: 3.405

4.  The SCHOOL of nature: I. Transmembrane signaling.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-01

5.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

Review 6.  Human T cell immunodeficiency: when signal transduction goes wrong.

Authors:  Eyal Grunebaum; Nigel Sharfe; Chaim M Roifman
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

8.  Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection.

Authors:  Jinglan Jin; Hongqin Xu; Ruihong Wu; Na Gao; Na Wu; Shibo Li; Junqi Niu
Journal:  J Cell Mol Med       Date:  2019-09-29       Impact factor: 5.310

Review 9.  SCHOOL model and new targeting strategies.

Authors:  Alexander B Sigalov
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.